ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
Go back to ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer| VERACYTE (NASDAQ: VCYT) | Delayed: 52.45 -1.18 (2.2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $53.63 | 52 Week High | $8.45 | |||
| Open | $53.72 | 52 Week Low | $4.21 | |||
| Day High | $54.72 | P/E | N/A | |||
| Day Low | $52.36 | EPS | $-1.52 | |||
| Volume | 184,821 | |||||
